Ariad Pharmaceuticals Inc fka ARIA

[jochenVt]

Not so positive as you are about this poster.
Yes, it says 40% reduction, but also that (only) 75% maintained MMR and 90% CCyR. I am not totally sure how this compares to the population that stayed on initial doses, but since they mention MCyR in the headline and then add these numbers later, I assume they are somewhat lower than the total population.
Now we know that these are heavily pretreated patients and responses are easier to achieve in earlier patient population, we just probably will not get these patients (at least not outside of t315i).
So I guess dose reduction will not come for free (or very cheap) in terms of effectiveness and we need to see what dose is the sweet (or least bitter) spot.